Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Twombly
Renee
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009154:Mutation; D011799:Quinazolines / Q000627:therapeutic use*; D016019:Survival Analysis; D017211:Treatment Failure; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib